Seroconversion rates following COVID-19 vaccination among patients with cancer
| Autor: | Joseph A. Sparano, Y. Goldstein, Kith Pradhan, Stuart Packer, Benjamin A. Gartrell, Niyati Goradia, Amit Verma, Lauren C. Shapiro, So Yeon Kim, Lucia Wolgast, Astha Thakkar, R. Alejandro Sica, Brian Ko, Roman Perez-Soler, Margaret E McCort, Sanjay Goel, Radhika Gali, Della F. Makower, Jesus D. Gonzalez-Lugo, Balazs Halmos, Lizamarie Bachier-Rodriguez, Shafia Rahman, Noah Kornblum |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Cancer Research Article Immunoglobulin G 03 medical and health sciences 0302 clinical medicine vaccine cancer Medicine Seroconversion biology business.industry Immunogenicity COVID-19 Cancer medicine.disease Vaccination Transplantation 030104 developmental biology Oncology Immunization 030220 oncology & carcinogenesis Immunology biology.protein Antibody business |
| Zdroj: | Cancer Cell |
| ISSN: | 1535-6108 |
| Popis: | As COVID-19 adversely affects patients with cancer, prophylactic strategies are critically needed. Using a validated antibody assay against SARS-CoV-2 spike protein, we determined a high seroconversion rate (94%) in 200 patients with cancer in New York City that had received full dosing with one of the FDA-approved COVID-19 vaccines. Comparing to solid tumors (98%), a significantly lower rate of seroconversion was observed in patients with hematological malignancies (85%), particularly recipients following highly immunosuppressive therapies such as anti-CD20 therapies (70%) and stem cell transplantation (73%). Patients receiving immune checkpoint inhibitor therapy (97%) or hormonal therapies (100%) demonstrated high seroconversion post-vaccination. Patients with prior COVID-19 infection demonstrated higher anti-spike IgG titers post-vaccination. Relatively lower IgG titers were observed following vaccination with the adenoviral than mRNA-based vaccines. These data demonstrate generally high immunogenicity of COVID-19 vaccination in oncology patients and identify immunosuppressed cohorts that need novel vaccination or passive immunization strategies. Graphical Abstract Evaluating the IgG levels against SARS-CoV-2 spike protein, Astha et al. demonstrate high rates of seroconversion in a diverse cohort of patients with cancer, while identifying lower immunogenicity in patients with hematological malignancies and in patients having received immunosuppressive therapies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|